US-based digital-twinning company Vent Creativity has secured the US Food and Drug Administration (FDA) approval for its AI-driven software solution, Hermes Knee.
Hermes Knee leverages deep learning to create surgical plans for total and partial knee arthroplasty procedures, focusing on mechanical, kinematic, and anatomical alignment.
The software aims to enhance surgical precision and outcomes through its approach.
Hermes Knee is designed based on the Minerva platform, which enables planning and analysis for various research applications.
The system enables users to interact with bone structures using intensity representations in a patented point cloud format.
Its features allow surgeons and radiologists to evaluate variations in human phenotypes and arthritic conditions, offering a comprehensive pre-operative assessment.
Vent Creativity said the cloud-based system operates through secure protocols, allowing surgeons to modify and annotate surgical plans as needed.
It generates reports for documentation, outcome studies, and reimbursement purposes.
The Hermes Knee system aims to support medical professionals in delivering patient-specific solutions, said the digital-twinning company.
Vent Creativity CEO Gilly Yildirim said: “We are a company of industry professionals who have worked on every aspect of the orthopaedic and medical technology and have identified patient-specific planning with digital-twin-informed technologies to be the missing link in the reported outcomes.
“Our unique approach to everything in healthcare is our strength as we have shown a free and fast-moving path to patents, publications, and regulatory submissions.
“We intend to prioritise research and development while sharing appropriate data with our partners for mutual growth of the healthcare sector desperate for collaborative instead of competitive growth for all.”
